MX2021005766A - Métodos de gestión de eventos adversos en pacientes con inflamación. - Google Patents

Métodos de gestión de eventos adversos en pacientes con inflamación.

Info

Publication number
MX2021005766A
MX2021005766A MX2021005766A MX2021005766A MX2021005766A MX 2021005766 A MX2021005766 A MX 2021005766A MX 2021005766 A MX2021005766 A MX 2021005766A MX 2021005766 A MX2021005766 A MX 2021005766A MX 2021005766 A MX2021005766 A MX 2021005766A
Authority
MX
Mexico
Prior art keywords
inflammation
methods
patients
adverse events
managing adverse
Prior art date
Application number
MX2021005766A
Other languages
English (en)
Inventor
Tatsuro Yoshida
Samuel O Sowemimo-Coker
Andrew Dunham
Original Assignee
Hemanext Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemanext Inc filed Critical Hemanext Inc
Publication of MX2021005766A publication Critical patent/MX2021005766A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Métodos de prevención y reversión de la inflamación.
MX2021005766A 2018-11-16 2019-11-14 Métodos de gestión de eventos adversos en pacientes con inflamación. MX2021005766A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862768667P 2018-11-16 2018-11-16
PCT/US2019/061565 WO2020102602A1 (en) 2018-11-16 2019-11-14 Methods for managing adverse events in patients with inflammation

Publications (1)

Publication Number Publication Date
MX2021005766A true MX2021005766A (es) 2021-10-01

Family

ID=69056115

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005766A MX2021005766A (es) 2018-11-16 2019-11-14 Métodos de gestión de eventos adversos en pacientes con inflamación.

Country Status (10)

Country Link
US (2) US20210401883A1 (es)
EP (1) EP3880214A1 (es)
JP (1) JP2022507537A (es)
CN (1) CN113365642A (es)
AU (1) AU2019381769A1 (es)
BR (1) BR112021008448A2 (es)
CA (1) CA3118792A1 (es)
IL (1) IL283066A (es)
MX (1) MX2021005766A (es)
WO (1) WO2020102602A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086835A1 (en) * 2022-10-20 2024-04-25 Hemanext Inc. Treatment of blood transfusion-dependent patients with hematologic malignancies
WO2024086834A1 (en) * 2022-10-20 2024-04-25 Hemanext Inc. Treatment of burn patients with hypoxic blood

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447987B1 (en) 1978-09-09 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Prolonged storage of red blood cells
US4769318A (en) 1986-06-03 1988-09-06 Ube Industries, Ltd. Additive solution for blood preservation and activation
US4880786A (en) 1987-01-14 1989-11-14 Ube Industries, Ltd. Additive solution for blood preservation and activation
US5476764A (en) 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US5624794A (en) 1995-06-05 1997-04-29 The Regents Of The University Of California Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas
US6162396A (en) 1997-04-26 2000-12-19 The Regents Of The University Of California Blood storage device and method for oxygen removal
US5789151A (en) 1997-05-15 1998-08-04 The Regents Of The University Of California Prolonged cold storage of red blood cells by oxygen removal and additive usage
US6413713B1 (en) 1998-10-30 2002-07-02 Hyperbaric Systems Method for preserving blood platelets
US9199016B2 (en) * 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
EP3384916A1 (en) * 2010-04-01 2018-10-10 Cytosorbents Corporation Sorbent for treating inflammation
EP2729000B1 (en) * 2011-07-05 2022-12-14 Hemanext Inc. A method for extended storage of red blood cells
CN107735095B (zh) * 2015-05-18 2022-06-14 希玛奈克斯特股份有限公司 储存全血的方法及其组合物
MX2018016103A (es) * 2016-06-23 2019-05-02 New Health Sciences Inc Metodos para manejar los efectos adversos en poblaciones de pacientes que necesitan una transfusion.

Also Published As

Publication number Publication date
AU2019381769A1 (en) 2021-06-03
CN113365642A (zh) 2021-09-07
BR112021008448A2 (pt) 2021-09-14
EP3880214A1 (en) 2021-09-22
US20230248767A1 (en) 2023-08-10
IL283066A (en) 2021-06-30
CA3118792A1 (en) 2020-05-22
JP2022507537A (ja) 2022-01-18
US20210401883A1 (en) 2021-12-30
WO2020102602A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
AU2018322319A1 (en) Antisense oligomers for treatment of conditions and diseases
NZ757213A (en) Compositions of plinabulin and use thereof
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
AU201814983S (en) Chair
CR20150403A (es) Sala de cine de múltiples niveles y una sola pantalla teniendo secciones de clases de servicio separadas
EP3750094A4 (en) SYSTEMS AND METHODS TO BE USED FOR DIGITAL IDENTITY MANAGEMENT
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MX2016014731A (es) Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
MX2021005766A (es) Métodos de gestión de eventos adversos en pacientes con inflamación.
AU201815816S (en) Inhaler
GB2548277A (en) Antibiofilm compositions
MX2023010063A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
EP3752158A4 (en) GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF
EP3749315A4 (en) ALPHA-POLYGLUTAMATED RALTITREXED AND USES THEREOF
SG10201901275PA (en) Storage device and server including the storage device
GB2558315A (en) Patterned surfaces
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
MX2020001844A (es) Metodos y sistema para aparatos dentales homogeneos.
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
EP3741748A4 (en) COMPOUND AND THEIR USE IN MEDICINE
IL290712A (en) Management of non-MS conditions in patients treated with ofatumumab
NZ738876A (en) Motile sperm domain containing protein 2 and inflammation